Hevolution Foundation announced a $20 million impact investment in Aeovian Pharmaceuticals to accelerate the development of therapies targeting aging and age-related diseases. According to the company, the funding aims to advance Aeovian’s pipeline of selective mTORC1 inhibitors, designed to slow biological aging and address multiple chronic conditions.
The company said the investment aligns with its mission to extend healthy human lifespan by supporting innovative approaches grounded in aging biology. Hevolution claims that Aeovian’s lead programs have shown promise in preclinical studies for treating neurodegenerative diseases and other age-associated disorders.
According to the company, this funding is part of a broader strategy to increase global investment in early-stage longevity biotechnology, an area it views as underfunded relative to its potential health impact. Hevolution said it prioritizes companies like Aeovian with scientifically validated platforms that could target fundamental aging mechanisms.
The company claims its support will help Aeovian advance candidates toward clinical trials and bridge gaps between discovery and patient application. Hevolution said the investment also reflects its commitment to fostering collaborations that can accelerate innovation in the longevity sector.
The company plans to continue backing biotechnology firms developing therapies to improve healthspan and treat age-related diseases worldwide.
